LL-37: Thousands of Papers, No Human Trials

Search LL‑37 and you will find thousands of papers, which is what makes it easy to sell. Read what they are and the picture changes: structural biology, cell culture, and animals. The most cited wound-healing result is a full-thickness wound model in diabetic mice, and its mechanism was confirmed by knocking down a transcription factor in cultured keratinocytes.^[1] That is respectable science, but it gives no reason to inject yourself with anything.

What LL-37 actually is

LL‑37 is the only cathelicidin-family antimicrobial peptide humans make. It is 37 residues long and part of the innate immune system’s first line of defense against bacteria, viruses, fungi and parasites. Interest in it is largely driven by antibiotic resistance: a broad-spectrum natural antimicrobial is an attractive starting point for new drugs.^[2]

That origin cuts both ways, and it is the part the marketing does not dwell on. A molecule your body already produces and regulates carefully is not obviously one to add from outside at an unregulated dose. The same review that surveys its antimicrobial promise also covers its influence on amyloid-related disease, because a peptide that aggregates and interacts with other aggregating proteins has consequences beyond killing bacteria.^[2]

The wound-healing study, described accurately

Researchers established a full-thickness wound closure model in diabetic mice and tested LL‑37 against LL‑37 plus an autophagy inhibitor. LL‑37 improved wound healing; adding the inhibitor reversed it. In cell culture, LL‑37 promoted keratinocyte migration under high glucose, and knocking down the transcription factor TFEB impaired that effect.^[1]

Why the paper count misleads

The most common way peptide marketing establishes credibility is volume: hundreds of citations, decades of research, a named human molecule. All of that is true, and none of it amounts to a controlled trial in people showing a benefit at a dose somebody sold you.

Thousands of papers on LL‑37, and we found no human clinical trial of it as a supplement.

• We found no human clinical trial of LL-37 supplementation for wound healing, weight, immunity or recovery.
• It is not an approved medicine. Anything sold under the name is a research chemical, with no guarantee of identity, purity or dose.
• Its biology is double-edged: an innate immune peptide with documented involvement in amyloid-related disease processes.
• Anyone with a diabetic wound has a condition that needs clinical wound care. A mouse study is not a treatment plan.

KPV, sold for gut and skin inflammation, is in the same position as LL‑37. For the class of drug that does have randomized evidence in diabetic foot disease, see GLP-1s, diabetic foot ulcers and blood flow. For the regulatory position on research-use peptides generally, see what FDA actually said about BPC-157, and /peptides lists the peptides we profile in full.